Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
Kodiak Sciences reported positive Phase 3 GLOW2 results for Zenkuda (tarcocimab tedromer) in diabetic retinopathy, demonstrating superiority over sham and supporting a multi-indication BLA submission. The company's pipeline advanced with enrollment complete in the DAYBREAK Phase 3 study for wet AMD and ongoing progress in the PEAK and PINNACLE studies for KSI-101.
Key figures
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 58200000
- Ga expenses
- 11200000
- Rd expenses
- 48500000
- Cash and equivalents
- 169500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.